Globenewswire·2025-12-11 13:00Core Insights - Aligos Therapeutics, Inc. announced positive data from four presentations at the HEP-DART 2025 Meeting, showcasing advancements in therapies for liver and viral diseases [1][2] Pevifoscorvir Sodium Data - The Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection demonstrated its potential as a first-line therapy, with complete 96-week and post-treatment follow-up data indicating continued efficacy [3][6] ALG-055009 Data - New in vivo data from studies on diet-induced obese mice showed that the combination of ALG-055009 with incretin receptor agonists resulted in significant weight loss, with SEMA monotherapy achieving a maximum of 23.9% body weight loss, while the combination with ALG-055009 led to an additional 8.6% decrease for a total of 33% [4][5] - TIRZEP monotherapy resulted in a maximum of 27.1% and 34.4% body weight loss for low and high doses respectively, with combinations yielding up to 40% weight loss [4][5] Synergistic Effects - The combination therapy of ALG-055009 with incretin receptor agonists primarily resulted in fat mass loss without significantly affecting lean mass or food consumption, indicating a beneficial addition to existing therapies for weight loss [5][6] Future Directions - The company expressed enthusiasm for the potential of both pevifoscorvir sodium and ALG-055009, highlighting their commitment to advancing next-generation therapies for chronic HBV and metabolic diseases [6][9]